Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
KOSKINAS, JOHN
NAMELS-18, NCT05946148: Novel Antidiabetic Medications and Their Effect on Liver Steatosis	Completed	N/A	78	Europe	Empagliflozin, E, Dulaglutide, D, Control Rx, C	National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, Hippocration General Hospital	Non-Alcoholic Fatty Liver Disease, Liver Steatosis	05/21	05/21
THANOPOULOU, ANASTASIA
NAMELS-18, NCT05946148: Novel Antidiabetic Medications and Their Effect on Liver Steatosis	Completed	N/A	78	Europe	Empagliflozin, E, Dulaglutide, D, Control Rx, C	National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, Hippocration General Hospital	Non-Alcoholic Fatty Liver Disease, Liver Steatosis	05/21	05/21
DEUTSCH, MELANIE
NAMELS-18, NCT05946148: Novel Antidiabetic Medications and Their Effect on Liver Steatosis	Completed	N/A	78	Europe	Empagliflozin, E, Dulaglutide, D, Control Rx, C	National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece, Hippocration General Hospital	Non-Alcoholic Fatty Liver Disease, Liver Steatosis	05/21	05/21